Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors
Pharma’s next competitive edge won’t come from a new molecule—it will come from faster market entry intelligence.
For years, IP teams and pharma strategists have treated “market entry” like a downstream event: a filing here, a patent challenge there, a…
